TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25579292
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg phenylephrine
Study: 25579292
Drug: 125 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 µg phenylephrine
Study: 25579292
Drug: 150 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µg phenylephrine
Study: 25579292
Drug: Additional doses
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional doses of phenylephrine
Study: 11099086
Drug: Ciprofloxacin suspension
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin suspension (10 mg/kg twice a day + im placebo; n = 95)
Study: 11099086
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone (50 mg/kg/day + placebo suspension; n = 106)
Study: 8345978
Drug: Intramuscular ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ceftriaxone
Study: 9124977
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg and Amiloride 5 mg orally added to furosemide treatment
Study: 9124977
Drug: Furosemide (large
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (large doses > or = 80 mg/24 h)
Study: 30144986
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic solution (1 mg/mL)
Study: 1351405
Drug: Continuous medication
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous medication with neuroleptic drugs
Study: 1351405
Drug: Intermittent medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent medication with crisis intervention
Study: 1351405
Drug: Intermittent medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent medication with early intervention
Study: 1351405
Drug: Oral neuroleptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral neuroleptics
Study: 31298607
Drug: Topical Chloramphenicol
Normalized name: chloramphenicol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB)
Study: 31298607
Drug: Topical Chloramphenicol
Normalized name: chloramphenicol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Chloramphenicol 0.5%-Betamethasone 0.2% (CB) associated with Sodium Hyaluronate/Trehalose/Carbomer Gel (HTC-gel)
Study: 30421481
Drug: Evolocumab on
Normalized name: Evolocumab only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab on top of atorvastatin 40 mg
Study: 22449170
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment applied by a physical therapist on the posterior deltoid, infraspinatus, and teres minor for 18 minutes, two times a week for 4 weeks.
Study: 8820892
Drug: Massage treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage treatment
Study: 17913231
Drug: Oestrogenic drugs
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogenic drugs
Study: 12513901
Drug: Self-administered therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered therapy
Study: 11422149
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS; 200 microg/day)
Study: 9495605
Drug: Sertraline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline treatment (11 weeks) in fibromyalgia patients
Study: 8285383
Drug: Stepwise lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepwise lowering of hemoglobin concentration through venesections (average decrease from 151 +/- 4 to 121 +/- 3 g/L)
Study: 3190968
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infusion at 20 mg h‐1
Study: 3190968
Drug: 0.08% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.08% bupivacaine infusion at 20 mg h‐1
Study: 28689647
Drug: Pilates method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pilates method physical activity programme (2 weekly sessions for 8 weeks)
Study: 25261268
Drug: Home-based telemonitored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based telemonitored Nordic walking (NW) training (n=77), five times weekly for eight weeks
Study: 18165600
Drug: Gabapentin 400
Normalized name: gabapentin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 400 mg preoperatively, administered every 6 hours up to a total of 1200 mg
Study: 15253736
Drug: Gentamicin and
Normalized name: Gentamicin and prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin and heparin (5 mg/mL)
Study: 15253736
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (5000 IU/mL) alone
Study: 11739835
Drug: Cannabinoid receptor
Normalized name: Cannabinoid receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabinoid receptor agonist nabilone
Study: 9415539
Drug: Modified total
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified total lymphoid irradiation plus low dose prednisone (TLI-LDP)
Study: 9415539
Drug: Sham TLI
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TLI plus identical prednisone therapy (sham TLI-LDP)
Study: 31662387
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (Enterococcus faecalis)
Study: 31662387
Drug: Concealed placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concealed placebo treatment
Study: 27243570
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT), 24 International Units
Study: 25981191
Drug: SB010 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB010 (10 mg, inhalation once daily for 28 days)
Study: 25981191
Drug: Placebo (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (inhalation once daily for 28 days)
Study: 24038301
Drug: Combined pharmacotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacotherapy and psychotherapy
Study: 16874872
Drug: S. boulardii
Normalized name: Lactobac. plantarum/S. boulardii/Pediococcus acidilactici 8 billion cell ORAL CAPSULE,DELAYED RELEASE (ENTERIC COATED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S. boulardii (250 mg bid)
Study: 12972483
Drug: Additional training
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional training on patients in hospital joint injection clinics
Study: 10633535
Drug: DHEA (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA (200 to 500 mg/day)
Study: 8733067
Drug: Converting-enzyme inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Converting-enzyme inhibitors
Study: 22698292
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen (HBO) administered at 2 atm twice a day for 40 treatments as an adjunct to surgery and antibiotics
Study: 22698292
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy alone (surgery and antibiotics)
Study: 20926017
Drug: Gentacoll implants
Normalized name: Gentacalm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentacoll implants (10 × 10 × 0.5 cm, 280 mg collagen sponge plus 200 mg gentamicin sulphate)
Study: 18926150
Drug: 80 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/d of atorvastatin (high-dose regimen)
Study: 18926150
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of atorvastatin (low-dose regimen)
Study: 15894964
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/d for 3 weeks)
Study: 9713273
Drug: Bolus 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus 5‐FU injection (2-4 min)
Study: 9713273
Drug: Short-term 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-term 5‐FU infusion (10-20 min)
Study: 7994982
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ticlopidine
Study: 7994982
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ticlopidine and 60-150 mg acetylsalicylic acid
Study: 7994982
Drug: Antiplatelet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet therapy (all groups combined)
Study: 11550964
Drug: Sulfasalazine 2
Normalized name: SULFASALAZINE 250MG/5ML SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine 2 g/day
Study: 2903927
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or Sulfasalazine 0.5 g/day
Study: 2903927
Drug: Sulfasalazine 1
Normalized name: sulfasalazine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfasalazine 1 g/day or 2 g/day
Study: 31722313
Drug: Perampanel, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel, a selective non‐competitive AMPA receptor antagonist, administered for 48 weeks
Study: 16226397
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy with CMF chemotherapy
Study: 16226397
Drug: Sequential radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential radiotherapy with CMF chemotherapy
Study: 12876090
Drug: β-carotene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-carotene (20 mg)
Study: 12876090
Drug: α-tocopherol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-tocopherol (50 mg)
Study: 9594145
Drug: Perindopril 2
Normalized name: perindopril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2 mg a day
Study: 26544854
Drug: Sham radial
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham radial extracorporeal shock wave therapy (sham rESWT)
Study: 22595151
Drug: Dispersible formulation
Normalized name: Disperse Blue 106
DrugBank: Disperse Blue 106 (DB14203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dispersible formulation of risperidone (2 mg)
Study: 22595151
Drug: Branded formulation
Normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded formulation of risperidone (2 mg)
Study: 16142041
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (alone or in combination with oral antidiabetic drugs)
Study: 12084083
Drug: Tacrolimus (FK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus (FK 506) applied 1 x daily for 5 days after the 4-day irritation period
Study: 10027655
Drug: 50 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 microg inhaled salmeterol
Study: 10027655
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral bambuterol
Study: 28103698
Drug: Histamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine (5 mg)
Study: 25027109
Drug: Oral recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral recombinant salmon calcitonin tablets (once daily for 1 year)
Study: 25027109
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for 1 year)
Study: 25027109
Drug: Oral recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral recombinant salmon calcitonin tablets (dosing at bedtime or with dinner)
Study: 25027109
Drug: Oral recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral recombinant salmon calcitonin tablets
Study: 19411087
Drug: rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (10 mg/d) for 20 weeks
Study: 19411087
Drug: rosuvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (10 mg/d) for 20 weeks + exercise training (3 d/wk from week 10 to week 20)
Study: 11430440
Drug: LIMIRT treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIMIRT treatment (840 nm; 3.0 J cm(‐2), pulse frequency 1 kHz)
Study: 8053582
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg) with high-dose midazolam (group 4)
Study: 8053582
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg) with low-dose midazolam (group 2)
Study: 1778138
Drug: Flumazenil (1
Normalized name: Flumazenil (18-F)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (1 mg)
Study: 28161119
Drug: Ibandronate 150
Normalized name: ibandronate 150 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 150 mg every 4 weeks
Study: 19112213
Drug: Short daily
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short daily hemodialysis (6 times per week for 1.5 to 2.75 hours)
Study: 24875804
Drug: Short daily
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short daily hemodialysis
Study: 9793661
Drug: Subcutaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous and peritoneal bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Study: 9793661
Drug: Subcutaneous bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bupivacaine (1.5 mg.kg‐1 bupivacaine 0.5%)
Study: 7697953
Drug: Buspirone (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (5, 10, and 20 mg)
Study: 7697953
Drug: Buspirone (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone (doses lower than 20 mg)
Study: 7697953
Drug: Sumatriptan (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (50, 100, and 200 mg)
Study: 7697953
Drug: Sumatriptan (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (doses unspecified)
Study: 2515136
Drug: bepridil (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: bepridil (100-400 mg/d)
Study: 2515136
Drug: propranolol (60-240
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (60-240 mg/d)
Study: 852404
Drug: BM 15.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM 15.075 at 450 mg
Study: 852404
Drug: BM 15.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM 15.075 at 600 mg
Study: 24950758
Drug: 2-micron continuous-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-micron continuous-wave laser treatment
Study: 23852296
Drug: 25 mg/day
Normalized name: estradiol 0.025 MG/Day Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/day mifepristone for 3 months
Study: 23852296
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day mifepristone for 3 months
Study: 15275754
Drug: 5.8% hypertonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.8% hypertonic saline (0.5 ml in each side for each bilateral injection)
Study: 10190658
Drug: Ropinirole (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropinirole (three times daily for 6 weeks)
Study: 10190658
Drug: Digoxin alone
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin alone (once daily)
Study: 10190658
Drug: Placebo (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (three times daily for 1 week)
Study: 7762498
Drug: Heparin-induced extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments
Study: 6383614
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug therapy
Study: 7762498
Drug: HELP treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HELP treatments
Study: 2082485
Drug: Dipyridamole 100
Normalized name: dipyridamole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole 100 mg t.i.d. plus warfarin (Study 1)
Study: 2082485
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release capsules of dipyridamole plus warfarin (Study 2)
Study: 2082485
Drug: Tablet form
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet form dipyridamole plus warfarin (Study 2)
Study: 371902
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg metoprolol once daily
Study: 371902
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg metoprolol once daily
Study: 371902
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg and 300 mg metoprolol
Study: 30706788
Drug: Ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (4 & 8 mg)
Study: 24969380
Drug: Galantamine (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (target dose: 24 mg)
Study: 24969380
Drug: Risperidone (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (target dose: 1.5 mg)
Study: 15735116
Drug: Gemcitabine (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1,000 mg/m(2), days 1 and 4), epirubicin (90 mg/m(2), day 1), and paclitaxel (175 mg/m(2), day 1)
Study: 15735116
Drug: Fluorouracil (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (500 mg/m(2), day 1), epirubicin (90 mg/m(2), day 1), and cyclophosphamide (500 mg/m(2), day 1)
Study: 12139821
Drug: 5 mg/24
Normalized name: Iron 5 MG/240 ML Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/24 h nitroglycerin patch
Study: 12139821
Drug: 10 mg/24
Normalized name: donepezil 10 mg/24 hr transdermal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/24 h nitroglycerin patch
Study: 12139821
Drug: 15 mg/24
Normalized name: Annovera, 0.013 mg-0.15 mg/24 hours vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/24 h nitroglycerin patch
Study: 12139821
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of nitroglycerin patches
Study: 10565799
Drug: mirtazapine (15-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: mirtazapine (15-60 mg/day)
Study: 10565799
Drug: citalopram (20-60
Approvals — FDA: no, EMA: no, PMDA: no
Description: citalopram (20-60 mg/day)
Study: 7881961
Drug: High-lipid intravenous
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-lipid intravenous nutrition (75% non-protein calories supplied as lipid)
Study: 7881961
Drug: Isocaloric isonitrogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isocaloric isonitrogenous glucose intravenous nutrition (100% non-protein calories supplied as glucose)
Study: 2404434
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg IM
Study: 2404434
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg IM
Study: 6776755
Drug: Levo-norgestrel (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo-norgestrel (250 microgram daily) and testosterone oenanthate (200 mg monthly)
Study: 6776755
Drug: Levo-norgestrel (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo-norgestrel (500 microgram daily) and testosterone oenanthate (200 mg monthly)
Study: 6776755
Drug: Levo-norgestrel (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levo-norgestrel (250 or 500 microgram daily) and testosterone oenanthate (200 mg monthly)
Study: 6776755
Drug: Recovery phase
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery phase after treatment
Study: 31532138
Drug: Otopoint pellet-pressing
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Otopoint pellet-pressing plus medication (Flunarizine 10 mg twice a day)
Study: 31532138
Drug: Medication (Flunarizine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (Flunarizine 10 mg twice a day)
Study: 26555069
Drug: cART plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: cART plus integrase inhibitor and CCR5 antagonist (cART+; raltegravir and maraviroc)
Study: 21308888
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for social phobia
Study: 19438993
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone (30 mg daily for 4 days)
Study: 17347181
Drug: Tetracaine 15
Normalized name: Chlorhexidine gluconate 500 microgram/mL and tetracaine 150 microgram/mL oromucosal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 15 mg in 3 ml of glucose 5% (hyperbaric)
Study: 17347181
Drug: Tetracaine 15
Normalized name: Chlorhexidine gluconate 500 microgram/mL and tetracaine 150 microgram/mL oromucosal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracaine 15 mg in 3 ml of CSF (isobaric)
Study: 16797292
Drug: Strict sodium
Normalized name: Euphrasia stricta extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict sodium diet (80 to 100 mmol sodium daily)
Study: 15012700
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no sertraline)
Study: 10802128
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion (40 mg per day)
Study: 10802128
Drug: Citalopram tablet
Normalized name: Citalopram Tablets
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram tablet (40 mg per day)
Study: 1839714
Drug: Inhaled anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled anesthetic
Study: 31158254
Drug: Gardasil-9 vaccine
Normalized name: Gardasil 9
DrugBank: Human papillomavirus type 58 L1 capsid protein antigen (DB10314)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gardasil-9 vaccine genotypes
Study: 15511336
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (50-150 mg/day for 5 days)
Study: 15511336
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant FSH (daily starting dose 75 IU for up to three consecutive cycles)
Study: 15511336
Drug: Low-dose recombinant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose recombinant FSH
Study: 8174308
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate super‐imposed on cyclical hormonal replacement therapy (HRT)